KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Treasury Shares (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Treasury Shares for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 1.88% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 1.88% year-over-year, with the annual reading at $2.6 million for FY2025, 1.88% down from the prior year.
  • Treasury Shares hit $19.5 million in Q4 2025 for Royalty Pharma, down from $20.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $21.5 million in Q2 2025 to a low of $3.1 million in Q2 2024.
  • Historically, Treasury Shares has averaged $11.4 million across 3 years, with a median of $8.9 million in 2023.
  • Biggest five-year swings in Treasury Shares: rose 25.63% in 2021 and later dropped 6.31% in 2023.
  • Year by year, Treasury Shares stood at $2.7 million in 2021, then increased by 3.35% to $2.8 million in 2022, then dropped by 6.31% to $2.6 million in 2023, then grew by 1.26% to $2.7 million in 2024, then fell by 1.88% to $2.6 million in 2025.
  • Business Quant data shows Treasury Shares for RPRX at $2.6 million in Q4 2025, $2.6 million in Q3 2025, and $2.6 million in Q2 2025.